730 related articles for article (PubMed ID: 8187370)
1. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced torsade de pointes.
Raehl CL; Patel AK; LeRoy M
Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
[TBL] [Abstract][Full Text] [Related]
3. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
[TBL] [Abstract][Full Text] [Related]
4. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Farkas A; Leprán I; Papp JG
J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
6. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
Hohnloser SH; Klingenheben T; Singh BN
Ann Intern Med; 1994 Oct; 121(7):529-35. PubMed ID: 8067651
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
Hohnloser SH; van de Loo A; Baedeker F
J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
9. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
[TBL] [Abstract][Full Text] [Related]
10. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
11. A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist.
Tan HH; Hsu LF; Kam RM; Chua T; Teo WS
Ann Acad Med Singap; 2003 May; 32(3):403-7. PubMed ID: 12854385
[TBL] [Abstract][Full Text] [Related]
12. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
13. Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia--evidence for a significant contribution of the "cardiac memory".
Haverkamp W; Hördt M; Breithardt G; Borggrefe M
Clin Cardiol; 1998 Jan; 21(1):55-8. PubMed ID: 9474467
[TBL] [Abstract][Full Text] [Related]
14. Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
D'Aloia A; Faggiano P; Brentana L; Boldini A; Pedrinazzi C; Procopio R; Dei Cas L
Int J Cardiol; 2005 Dec; 105(3):337-9. PubMed ID: 15985302
[TBL] [Abstract][Full Text] [Related]
15. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
Fitton A; Sorkin EM
Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
[TBL] [Abstract][Full Text] [Related]
16. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
17. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
Silvetti MS; Drago F; Bevilacqua M; Ragonese P
Ital Heart J; 2001 Mar; 2(3):231-6. PubMed ID: 11305536
[TBL] [Abstract][Full Text] [Related]
18. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
[TBL] [Abstract][Full Text] [Related]
19. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
Yamada S; Kuga K; Yamaguchi I
Jpn Circ J; 2001 Mar; 65(3):236-8. PubMed ID: 11266201
[TBL] [Abstract][Full Text] [Related]
20. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
